ARWR - Arrowhead Pharmaceuticals, Inc.
| Previous close | 33.71 |
| Open | 33.71 |
| Bid | 32.27 x 900 |
| Ask | 34.50 x 1100 |
| Day's range | 31.57 - 34.22 |
| 52-week range | 19.51 - 73.72 |
| Volume | 1,874,453 |
| Avg. volume | 1,511,461 |
| Market cap | 3.427B |
| Beta (5Y monthly) | 1.81 |
| PE ratio (TTM) | 365.98 |
| EPS (TTM) | 0.09 |
| Earnings date | 03 Aug 2020 - 07 Aug 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 62.22 |
- Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences
Arrowhead Pharmaceuticals will present at Jefferies and Goldman Sachs healthcare conferences in June 2020
- Motley Fool
Is Arrowhead Pharmaceuticals a Buy?
The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.
- Motley Fool
Will Arrowhead Pharmaceuticals Be a Biotech Winner?
A leading company in the field of gene silencing is on track to develop several breakthrough therapies.
- Simply Wall St.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Investors in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) had a good week, as its shares rose 4.9% to close at...
- Motley Fool
Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2020 Earnings Call Transcript
Thank you for joining us today to discuss Arrowhead's results for its fiscal second quarter ended March 31, 2020. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, Chief Medical Officer who will discuss our clinical programs; Dr. Curt Bradshaw, our Chief Scientific Officer who will discuss our discovery, platform development and manufacturing efforts; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials.
- Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
Arrowhead Pharmaceuticals reports fiscal Q2 2020 earnings
- Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences
Arrowhead will present at upcoming May 2020 investor conferences
- Business Wire
Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given
Bruce Given retires from Arrowhead Pharmaceuticals
- Motley Fool
Is Arrowhead Pharmaceuticals Close to a Cure for HBV?
The collaboration between a pharmaceutical giant and a mid-cap biotech company may have accomplished the impossible.
- Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results
Arrowhead Pharmaceuticals will webcast fiscal 2020 second quarter earnings on May 7, 2020
- Simply Wall St.
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks
It hasn't been the best quarter for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders, since the share price...
- Business Wire
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis
Arrowhead files to begin Phase 1/2a study of ARO-ENaC, RNAi therapeutic for Cystic Fibrosis
- Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead announces March 2020 inducement grants
- Business Wire
Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
Arrowhead provides update related to COVID-19 efforts
- Simply Wall St.
Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified?
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. This report will, first...
- Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
Arrowhead dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD for alcohol related and nonalcohol related liver diseases
- Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences
Arrowhead Pharmaceuticals will participate in multiple conference presentations in March 2020
- Zacks
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
Style Box ETF report for FNY
- Zacks
Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?
We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.
- Simply Wall St.
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) A Volatile Stock?
If you're interested in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), then you might want to consider its beta (a...
- Zacks
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
Style Box ETF report for FNY
